Status:

COMPLETED

Skeletal Muscle Lipid and Insulin Resistance: Effects of Physical Activity and Weight Loss

Lead Sponsor:

University of Pittsburgh

Collaborating Sponsors:

American Diabetes Association

Conditions:

Type 2 Diabetes Mellitus

Eligibility:

All Genders

60-75 years

Phase:

NA

Brief Summary

102 late- life adults at risk for developing type 2 diabetes mellitus, will be randomized to one of three interventions designed to improve insulin sensitivity thereby potentially preventing future pr...

Detailed Description

The primary objective of this project will be to examine the role of skeletal muscle lipid and capacity for fat oxidation in insulin resistance in older adults who either are at high risk for the deve...

Eligibility Criteria

Inclusion

  • 60-75 years of age
  • Stable weight (No Gain/Loss of \> 10 lbs in 6 months)
  • Impaired Glucose Tolerance or Newly, untreated, undiagnosed type 2 diabetes
  • Sedentary
  • Non-smoker
  • BMI 25.0-38.0 KG/M2
  • Resting Blood Pressure ≤ 150mmHg systolic and ≤ 95 mmHg diastolic
  • IGT: Fasting Glucose \> 100, \< 126 2-Hour OGTT \> 140 but \< 200
  • T2D: Fasting Glucose \> 126 \< 2000 2-Hour OGTT \> 200
  • Note from PCP/Cardiologist for exercise clearance if positive stress test symptoms were observed from GXT

Exclusion

  • Clinically significant CVD including h/o MI
  • Peripheral Vascular Disease
  • Hepatic, renal, muscular/neuromuscular, or active hematologic/oncologic disease
  • Clinically diminished pulse
  • Presence of bruits in lower extremities
  • Previous history of pulmonary emboli
  • Peripheral Neuropathy
  • Currently not engaged in a regular program and have a VO2 max pre-training value \> 55 ml/kg-fat free mass-min., indicative of moderate fitness.
  • Anemia (Hematocrit \< 34%)
  • Any contraindications to moderate exercise (Please specify)
  • Inability and/ or unwillingness to comply with the protocol as written
  • Active alcohol or substance abuse (Past 5 Years)
  • Total cholesterol \> 300 mg/dL
  • Triglyceride \> 350 mg/dL
  • ALT \> 80, AST \> 80, Alk Phos \> 240
  • Proteinuria (defined as \>1 + on routine dipstick), hypothyroidism (sTSH\>8)
  • Therapeutic Doses of Nicotinic Acid
  • Oral glucocorticoids
  • Females currently on hormone replacement therapy (HRT) less than 6 months
  • Claustrophobia
  • Previous difficulty with lidocaine or other local anesthetic
  • Stress test symptoms:
  • Positive ECG (\> 2mm ST segment depression) without PCP cardiologist permission to participate
  • Signs or symptoms of cardiovascular decomposition (hypotensive response to exercise)
  • Onset of angina or angina like symptoms, shortness of breath, change in heart rhythm, signs of poor perfusion (light-headedness), tightness,
  • Hypotension

Key Trial Info

Start Date :

June 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2011

Estimated Enrollment :

102 Patients enrolled

Trial Details

Trial ID

NCT00766298

Start Date

June 1 2004

End Date

August 1 2011

Last Update

July 31 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15213

Skeletal Muscle Lipid and Insulin Resistance: Effects of Physical Activity and Weight Loss | DecenTrialz